Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients
Status:
Recruiting
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
General objective of the study To assess the efficacy and safety of enoxaparin in
hospitalized patients with moderate to severe COVID-19 (Coronavirus Disease 2019) infection.
Study Design
The study consists of two parts:
- a phase II single-arm interventional prospective study including all patients treated
with the study drug;
- an observational prospective cohort study including all patients screened for receiving
the study drug but not included in the phase II study.
Patients will be enrolled from "date of study approval" for 1 month. Each patient will be
followed-up for a minimum of 90 days after COVID19 diagnosis.
Phase:
Phase 2
Details
Lead Sponsor:
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi IRCCS Azienda Ospedaliero-Universitaria di Bologna